Article Text

Download PDFPDF
Short report
Pancreatic cancer cluster region identified in BRCA2
  1. Jia Sheng Chian,
  2. Wenzheng Xu,
  3. San Ming Wang
  1. Faculty of Health Sciences, University of Macau, Macau, Macau
  1. Correspondence to Professor San Ming Wang, University of Macau Faculty of Health Sciences, Macau, Macao; sanmingwang{at}


Pancreatic cancer has a poor prognosis. Lack of diagnostic markers prevents its early diagnosis and treatment. Pathogenic germline variation in BRCA1 and BRCA2 (BRCA) is genetic predisposition for cancer. The location of variants in different regions in BRCA is non-randomly enriched in different types of cancer as shown by the breast cancer cluster region (BCCR), ovarian cancer cluster region (OCCR) and prostate cancer cluster region (PrCCR). Although pathogenic BRCA variation also contributes to pancreatic cancer, no pancreatic cancer cluster region (PcCCR) in BRCA1 or BRCA2 has been identified due to the relatively low incidence of pancreatic cancer and the lack of sufficient variation data from pancreatic cancer. Through comprehensive data mining, we identified 215 BRCA pathogenic variants (PVs) (71 in BRCA1 and 144 in BRCA2) from 27 118 pancreatic cancer cases. Through mapping the variants, we identified a region non-randomly enriched in pancreatic cancer between BRCA2 c.3515 and c.6787. This region contained 59 BRCA2 PVs and included 57% of pancreatic cancer cases (95% CI 43% to 70%). The PcCCR did not overlap with the BCCR and PrCCR but overlapped with the BRCA2 OCCR, highlighting that this region may play similar aetiological roles in pancreatic cancer and ovarian cancer.

  • Pancreatic Diseases

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors JSC: conceptualisation, data analysis, methodology, visualisation and writing; WX: data analysis; SMW: supervision, methodology, revision and funding acquisition.

  • Funding This work was supported by grants from the Macau Science and Technology Development Fund (085/2017/A2, 0077/2019/AMJ and 0032/2022/A1), the University of Macau (SRG2017-00097-FHS, MYRG2019-00018-FHS and 2020-00094-FHS) and the Faculty of Health Sciences, University of Macau (FHSIG/ SW/0007/2020P, MOE Frontiers Science Center for Precision Oncology pilot grant, and a startup fund) to SMW.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.